We've been closely monitoring the transformative impact of AI in healthcare diagnostics, as highlighted in our latest Market Mixers podcast. The podcast outlines three waves of AI development in healthcare: imaging analysis, workflow optimisation, and now language and multimodal AI systems.
When evaluating AI diagnostics companies, we assess four critical factors: care pathway integration, evidence quality, regulatory pathways, and reimbursement structures.
Companies like RadNet and Artrya demonstrate the potential of AI in healthcare, with Artrya's share price increasing 8.5x in the past year while addressing a $5 billion market. The podcast notes that "compared to HeartFlow's $2.8 billion valuation, Artrya remains undervalued given its superior automation, patient outcomes, and hospital economics." RadNet has shown impressive results too, with studies indicating a 21% improvement in breast cancer detection using its DeepHealth AI.
AI diagnostics are entering what the article describes as a "fintech moment," reshaping information flow, improving accuracy, and accelerating care delivery across the healthcare sector. To watch or listen to the episode, click the link below.